Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Cytokine Induced Memory-Like Natural Killer Cells Combined With Atezolizumb in Subjects With Relapsed or Refractory Acute Myelogenous Leukemia

NCT07011004 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07011004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07011004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Cytokine Induced Memory-Like Natural Killer Cells Combined With Atezolizumb in Subjects With Relapsed or Refractory Acute Myelogenous Leukemia
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
May 30, 2025
Completion date
May 31, 2028
Enrollment
18 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia refractory, acute myeloid leukemia, in relapse